Highest-materiality recent filing
Syndax Q1 revenue up 224% to $64.9M; net loss narrows to $42.7M from $84.8M
Revuforj net revenue $48.9M (+144% YoY, +11% QoQ); total prescriptions up ~160% YoY.
Syndax Q4 Revuforj $44.2M (+38% QoQ); Niktimvo $56M; net loss $68M
Total revenue $68.7M in Q4 and $172.4M in FY2025, driven by Revuforj and Niktimvo launches.
Syndax reports preliminary 2025 Revuforj $125M, Niktimvo $152M net rev, cash $394M
Revuforj preliminary net revenue $44M (Q4) and $125M (FY), up 38% QoQ.
Syndax reports Q3 2025 revenue $45.9M, Revuforj net sales $32M; FDA approval for NPM1m AML on Oct 24
Total revenue $45.9M (Revuforj net $32.0M, +12% vs Q2; Niktimvo collab $13.9M).
Syndax receives FDA approval for Revuforj in NPM1-mutated R/R AML, second indication in <1 year
FDA approved Revuforj (revumenib) for R/R AML with NPM1 mutation in patients aged ≥1 year.
Syndax Q2 Revuforj revenue $28.6M (+43% QoQ); sNDA for mNPM1 AML with Priority Review
Revuforj net revenue $28.6M in Q2 2025, 43% increase over Q1 2025.
Syndax names Dr. Nicholas Botwood Head of R&D and CMO, replacing Neil Gallagher
Dr. Nicholas Botwood appointed Head of R&D and CMO, effective May 12, 2025; succeeds Dr. Neil Gallagher who is departing.
Syndax Q1 Revuforj rev $20M, Niktimvo rev $13.6M; sNDA for mNPM1 AML
Revuforj net revenue $20.0M in first full quarter; Niktimvo net revenue $13.6M (Incyte reported) in first partial quarter.
Syndax Q4 Revuforj revenue $7.7M; net loss $94.2M; cash $692.4M
Q4 2024 Revuforj net product revenue $7.7M in first five weeks of U.S. launch.
Syndax eliminates Chief Medical Officer role; Dr. Catherine Madigan departs
CMO Catherine Madigan, M.D. ceased employment effective December 20, 2024, after position eliminated.
FDA approved Revuforj for R/R acute leukemia with KMT2A translocation in patients aged 1+ years.
Syndax reports positive pivotal Phase 2 results for revumenib in R/R mNPM1 AML; CR/CRh 23%
Primary endpoint met: CR/CRh rate 23% (15/64; 95% CI 14%–36%; p=0.0014) in efficacy-evaluable adult patients.
Syndax Q3 net loss $84.1M; revumenib PDUFA Dec 26; Niktimvo approved; $350M royalty funding
Net loss $84.1M ($0.98/share) vs $51.1M ($0.73) in Q3 2023; R&D $71.0M, SG&A $31.1M.
Syndax sells 13.8% royalty on Niktimvo (axatilimab) to Royalty Pharma for $350M upfront
Royalty Pharma acquires right to 13.8% of net sales of Niktimvo (axatilimab) in US and territories.
Syndax Q2 net loss $68.1M, revumenib PDUFA extended to Dec 26, 2024
Net loss of $68.1M ($0.80/sh) vs $44.6M ($0.64/sh) in Q2 2023; cash $454.6M as of June 30.
Syndax Q1 net loss $72.4M ($0.85/shr); revumenib NDA & axatilimab BLA under Priority Review
Cash, equivalents and investments $522M; management believes sufficient for operations through 2026.
Nicholas A.J. Botwood, BSC (HONS), MB BS, MFPM, FRCP, will join the Company as Head of Research and Development, Chief Medical Officer, effective May 12, 2025.
Neil Gallagher, M.D. Ph.D, President, Head of Research and Development of the Company, notified the Company of his intention to resign from his position as President, Head of Research and Development.
On May 15, 2024, the Board of Directors (the “ Board ”) of Syndax Pharmaceuticals, Inc. (the “ Company ”), unanimously voted to elect Aleksandra Rizo, M.D., Ph.D. to the Board, effectively immediately
On May 14, 2024, Briggs W. Morrison, M.D. advised the Board that he will resign from his position as a Class III member of our Board effective immediately.
Max materiality 0.95 · Median 0.75 · Most common event earnings